Biohaven Stock Gets Higher EPS Estimate from HC Wainwright

Biohaven Ltd. (NYSE:BHVN) – Equities researchers at HC Wainwright raised their FY2026 earnings estimates for shares of Biohaven in a note issued to investors on Monday, November 2nd. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of ($3.00) per share for the year, up from their prior estimate of ($3.44). HC Wainwright currently has a “Neutral” rating and a $10.00 price target on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($3.11) per share. HC Wainwright also issued estimates for Biohaven’s Q4 2026 earnings at ($0.35) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at ($2.14) EPS, FY2029 earnings at ($1.40) EPS and FY2030 earnings at $1.86 EPS.

A number of other equities research analysts have also recently commented on the stock. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Biohaven in a report on Thursday, October 8th. Weiss Ratings raised Biohaven from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday. TD Cowen restated a “buy” rating on shares of Biohaven in a research note on Wednesday, August 26th. Citigroup reaffirmed a “buy” rating on shares of Biohaven in a research report on Friday, September 18th. Finally, Wall Street Zen upgraded Biohaven from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.06.

Biohaven Stock Down 2.5%

BHVN opened at $15.22 on Thursday. Biohaven has a twelve month low of $7.48 and a twelve month high of $18.24. The company’s 50-day moving average price is $13.71 and its two-hundred day moving average price is $12.30. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -3.94 and a beta of 1.36. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 21.23.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC grew its position in shares of Biohaven by 1,145.9% during the 1st quarter. Janus Henderson Group PLC now owns 17,534,612 shares of the company’s stock valued at $148,214,000 after purchasing an additional 16,127,247 shares in the last quarter. BlackRock Inc. bought a new stake in Biohaven during the second quarter valued at $196,574,000. Jupiter Topco LLC bought a new stake in Biohaven during the second quarter valued at $127,852,000. Stempoint Capital LP purchased a new position in Biohaven during the first quarter worth about $13,489,000. Finally, Bank of America Corp DE purchased a new position in Biohaven during the second quarter worth about $21,990,000. 88.78% of the stock is owned by institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE:BHVN) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for neurological and neuropsychiatric diseases, as well as certain immunological and rare disorders. The company’s research activities include small-molecule medicines, monoclonal antibodies and other innovative therapeutic approaches.

Biohaven’s pipeline has included investigational treatments for conditions such as migraine, obsessive-compulsive disorder, spinal muscular atrophy, amyotrophic lateral sclerosis, mood disorders and autoimmune diseases.